Compare WKEY & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | RLYB |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Switzerland | United States |
| Employees | 202 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 92.3M |
| IPO Year | N/A | 2021 |
| Metric | WKEY | RLYB |
|---|---|---|
| Price | $6.87 | $15.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 83.4K | 39.3K |
| Earning Date | 01-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $4.75 | $0.39 |
| 52 Week High | $19.80 | $17.57 |
| Indicator | WKEY | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 55.98 |
| Support Level | $6.43 | $15.59 |
| Resistance Level | $6.94 | $16.50 |
| Average True Range (ATR) | 0.43 | 0.37 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 21.74 | 18.68 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.